Experts Available

Filters close
Released: 7-Aug-2009 9:00 AM EDT
Expert Available for Commentary on Recent FDA Analysis of TNF Blockers
Cancer Research Institute

The FDA announced on Aug 4 2009 that tumor necrosis factor (TNF) blockers used in the treatment of immune disorders carry an increased risk of lymphoma and other cancers in children and adolescents. The discoverer of TNF-alpha, Lloyd J. Old, M.D., a tumor immunologist, is available for comment.

Released: 29-Apr-2009 11:20 AM EDT
PROVENGE Cancer Vaccine Heralds New Dawn in Cancer Therapy
Cancer Research Institute

Dendreon's PROVENGE for the treatment of advanced prostate cancer is the first active cellular immunotherapy to prolong patient survival, according to data from a pivotal phase III clinical trial announced at yesterday's AUA annual meeting in Chicago. This milestone achievement for the field of tumor immunology heralds the advent of a new dawn in cancer therapy, say experts, where immune-based agents will form a new, fourth modality to complement today's standard chemical, radiological, and surgical therapies.

  • Previous Page
  • Next Page

Showing results

12 of 2